VHL and renal cell carcinoma: A somatic mutation of the Von Hippel–Lindau (VHL) gene is the most frequent genetic change observed in RCC [2], and recent efforts have targeted the VHL–hypoxia inducible factor (HIF)-mediated hypoxia-induced gene pathway for RCC therapy [3].